Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II-III Melanoma

PURPOSE: Biomarkers are needed to stratify patients with stage II-III melanoma for clinical trials of adjuvant therapy because, while immunotherapy is protective, it also confers the risk of severe toxicity. We previously defined and validated a 53-immune gene melanoma immune profile (MIP) predictiv...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Clin Cancer Res
Prif Awduron: Gartrell, Robyn D., Marks, Douglas K., Rizk, Emanuelle M., Bogardus, Margaret H., Gérard, Camille L., Barker, Luke W., Fu, Yichun, Esancy, Camden L., Li, Gen, Ji, Jiayi, Rui, Shumin, Ernstoff, Marc S., Taback, Bret, Pabla, Sarabjot, Chang, Rui, Lee, Sandra J., Krolewski, John J., Morrison, Carl, Saenger, Yvonne M.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2019
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6594682/
https://ncbi.nlm.nih.gov/pubmed/30647081
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-2847
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg